Teva Pharmaceutical Industries Ltd (TEVJF) Gross Margin (2009 - 2026)

Teva Pharmaceutical Industries' (TEVJF) quarterly Gross Margin came in at 51.98% in Q2 2026, up 164.0% YoY from 19.69% in Q2 2025, and up 4.96% on a QoQ basis from 49.52% in Q1 2026.

Teva Pharmaceutical Industries Ltd (TEVJF) Gross Margin (2009 - 2026) Analysis & Trends

Teva Pharmaceutical Industries (TEVJF) has 18 years of Gross Margin data on file, last reported at 51.98% in Q2 2026.

  • Quarterly Gross Margin rose 164.0% year-over-year to 51.98% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 52.47% (down 144.0% YoY) and the FY2025 annual result came in at 51.79%, up 305.0% from the prior year.
  • Gross Margin advanced to 51.98% in Q2 2026, from 49.52% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 73.14% in Q4 2024 to a low of 43.21% in Q1 2023.
  • A 5-year average of 50.24% and a median of 48.42% in 2024 frame the typical range for Gross Margin.
  • Annual changes were most pronounced in 2024 — Gross Margin jumped 1893 bps — and 2025, when it sank 1676 bps.
  • Tracing TEVJF's Gross Margin over 5 years: stood at 45.57% in 2022, then advanced by 19 bps to 54.21% in 2023, then soared by 35 bps to 73.14% in 2024, then dropped by 23 bps to 56.38% in 2025, then dropped by 8 bps to 51.98% in 2026.
  • The last three Gross Margin figures came in at 51.98% (Q2 2026), 49.52% (Q1 2026), and 56.38% (Q4 2025), per Business Quant data.

Peer Comparison

Historic Data

Download Data
DateValue
Jun 30, 2026 51.98%
Mar 31, 2026 49.52%
Dec 31, 2025 56.38%
Sep 30, 2025 51.43%
Jun 30, 2025 50.34%
Mar 31, 2025 48.24%
Dec 31, 2024 73.14%
Sep 30, 2024 49.58%
Jun 30, 2024 48.61%
Mar 31, 2024 46.37%
Dec 31, 2023 54.21%
Sep 30, 2023 48.08%
Jun 30, 2023 46.31%
Mar 31, 2023 43.21%
Dec 31, 2022 45.57%
Sep 30, 2022 46.43%
Jun 30, 2022 47.39%
Mar 31, 2022 47.53%
Dec 31, 2021 50.00%
Sep 30, 2021 46.15%